Stereotaxis Business Summary

Stereotaxis, Inc. (STXS) operates a high-margin "razor and razor blade" business model centered on its proprietary Robotic Magnetic Navigation (RMN) technology for minimally invasive endovascular procedures. Revenue is generated through three primary segments: Systems (capital sales of the Genesis RMN and the newly FDA-cleared GenesisX systems), Disposables (recurring sales of proprietary catheters such as the MAGiC ablation and MAGiC Sweep mapping families), and Service/Royalty (maintenance contracts and licensing). As of early 2026, the company has transitioned toward a consumable-driven growth strategy, with recurring revenue accounting for approximately 75% of total sales at gross margins exceeding 65%. In the competitive landscape, Stereotaxis maintains a unique niche as the only commercial provider of magnetic-based robotic navigation, positioning itself against traditional manual catheter manufacturers like Medtronic and Johnson & Johnson, while competing for hospital capital budgets against robotic surgery peers such as Atricure, PROCEPT BioRobotics, and CMR Surgical. Originally founded in 1990 by neurosurgeon Dr. Michael G. Brophy and Behzad Ghazi, Stereotaxis is currently led by Chairman and CEO David L. Fischel, who assumed the role in 2017 after a decade as a principal at DAFNA Capital Management. Fischel is supported by CFO Kimberly R. Peery, a long-tenured executive who has overseen the company’s financial restructuring since 2019. The leadership team is bolstered by a high-pedigree Board of Directors, including Dr. Myriam Curet (Executive VP and Chief Medical Officer of Intuitive Surgical), Dr. Nathan Fischel (Founder of DAFNA Capital), and Ross B. Levin (Director of Research at Arbiter Partners). Notable institutional backing includes concentrated positions from DAFNA Capital Management, Arbiter Partners, and Lagoda Investment Management, alongside passive stability from major index investors like BlackRock and Vanguard.